current
worldwid
outbreak
new
type
coronaviru
covid
origin
wuhan
china
spread
countri
includ
japan
korea
itali
world
health
organ
declar
becom
global
health
concern
caus
sever
respiratori
tract
infect
human
current
evid
indic
spread
human
via
transmiss
wild
anim
illeg
sold
huanan
seafood
wholesal
market
phylogenet
analysi
show
new
member
coronavirida
famili
distinct
sarscov
ident
approxim
merscov
ident
approxim
know
origin
pathogen
critic
develop
mean
block
transmiss
vaccin
notabl
share
high
level
genet
similar
bat
coronaviru
obtain
bat
yunnan
howev
bat
immedi
sourc
typic
symptom
fever
sore
throat
fatigu
cough
dyspnea
coupl
recent
exposur
period
day
ci
unusu
case
also
report
incub
period
long
day
notabl
long
incub
time
mean
adjust
screen
control
polici
incub
period
low
probabl
event
expert
suggest
day
quarantin
basic
reproduct
number
modelbas
larg
depend
epidemiolog
set
import
paramet
determin
intrins
transmiss
earli
outbreak
data
larg
follow
exponenti
growth
differ
model
base
clinic
progress
diseas
devis
estim
basic
reproduct
number
earli
stage
pandem
doubl
size
everi
day
basic
reproduct
number
estim
anoth
studi
estim
basic
reproduct
number
rang
howev
determinist
compartment
model
base
likelihood
model
analysi
show
control
reproduct
number
may
high
author
note
basic
reproduct
number
higher
estim
account
gener
viral
transmiss
intens
social
contact
basic
reproduct
number
estim
major
studi
rang
slightli
higher
sar
rapid
accur
detect
crucial
control
outbreak
commun
hospit
current
diagnost
test
coronaviru
includ
reversetranscript
polymeras
chain
reaction
rtpcr
realtim
rtpcr
rrtpcr
revers
transcript
loopmedi
isotherm
amplif
rtlamp
rtlamp
similar
sensit
rrtpcr
highli
specif
use
detect
merscov
accord
current
diagnost
criteria
found
china
nation
health
commiss
laboratori
examin
includ
nasopharyng
oropharyng
swab
test
becom
standard
assess
diagnosi
infect
identifi
patient
earlier
two
onestep
quantit
rtpcr
qrtpcr
assay
develop
detect
two
differ
region
n
genom
three
novel
rtpcr
assay
target
rnadepend
rna
polymeras
rdrp
helicas
hel
spike
nucleocapsid
n
gene
develop
among
three
novel
assay
assay
lowest
limit
detect
vitro
highli
sensit
specif
assay
may
help
improv
laboratori
diagnosi
sarscov
e
gene
assay
sensit
rdrp
gene
assay
combin
onestep
rtpcr
system
e
gene
pcr
suffici
diagnos
infect
rdrp
protocol
recommend
confirm
posit
result
overal
posit
rate
rtpcr
detect
infect
case
one
hospit
wuhan
posit
rate
pcr
oropharyng
swab
high
patient
posit
oral
swab
test
seri
patient
confirm
infect
patient
rtpcr
posit
first
time
test
throat
swab
sputum
sampl
rtpcr
result
usual
becom
posit
sever
day
day
autom
solut
molecular
diagnost
handl
larg
number
sampl
scale
keep
pace
fluctuat
demand
good
analyt
perform
molecular
assay
detect
highthroughput
platform
coba
observ
minim
handson
time
offer
fast
reliabl
result
current
laboratori
test
timeconsum
shortag
commerci
kit
delay
diagnosi
patient
suffer
fever
sore
throat
fatigu
cough
dyspnea
coupl
recent
exposur
infect
diagnos
typic
chest
computer
tomographi
ct
characterist
despit
neg
rtpcr
result
patient
posit
rtpcr
result
posit
chest
ct
scan
belong
coronavirida
famili
therefor
surpris
imag
find
similar
sarscov
merscov
typic
ct
find
includ
bilater
pulmonari
parenchym
groundglass
consolid
pulmonari
opac
sometim
round
morpholog
peripher
lung
distribut
eightysix
percent
patient
show
groundglass
opac
consolid
one
lobe
bilater
involv
affect
initi
chest
ct
scan
notabl
lung
cavit
discret
pulmonari
nodul
pleural
effus
lymphadenopathi
absent
lung
abnorm
chest
ct
scan
sever
approxim
day
initi
onset
symptom
chest
ct
scan
use
assess
sever
also
manifest
chest
ct
imag
abnorm
asymptomat
patient
rapid
evolut
focal
unilater
diffus
bilater
groundglass
opac
progress
coexist
consolid
within
week
combin
assess
imag
featur
clinic
laboratori
find
could
facilit
earli
diagnosi
pneumonia
diagnost
criteria
expand
laboratori
examin
chest
ct
imag
patient
diagnos
februari
classic
public
health
measur
includ
isol
quarantin
social
distanc
commun
contain
use
curb
pandem
respiratori
diseas
china
prepar
sinc
contain
futur
pandem
appli
lesson
learn
sar
pandem
china
issu
largest
quarantin
histori
resid
live
mainland
china
lockedin
citi
public
transport
includ
buse
train
ferri
airport
shutdown
given
trajectori
outbreak
chines
govern
scale
effort
keep
pace
rapid
increas
case
geograph
spread
wuhan
govern
made
full
use
gym
two
convent
center
transform
makeshift
hospit
bed
one
night
isol
patient
healthi
control
makeshift
hospit
construct
isol
bed
quickli
expand
begin
outbreak
separ
infect
patient
noninfect
individu
swift
decis
respons
china
contribut
reduc
control
reproduct
number
transmiss
risk
due
power
effect
isol
measur
taken
chines
govern
increas
began
slow
februari
accord
data
releas
china
nation
health
commiss
current
evid
random
control
trial
rct
recommend
specif
treatment
patient
suspect
confirm
infect
lopinavir
lpv
inhibit
proteas
activ
coronaviru
vitro
anim
studi
retrospect
matchedcohort
studi
includ
sar
patient
show
lpvritonavir
initi
treatment
associ
reduc
death
rate
vs
proteas
inhibitor
lpv
effect
treatment
base
experi
accumul
sar
mer
outbreak
indic
potenti
treatment
option
ribavirin
guanosin
analogu
antivir
compound
use
treat
sever
viru
infect
includ
respiratori
syncyti
viru
hepat
c
viru
viral
hemorrhag
fever
promis
result
obtain
ribavirin
merscov
rhesu
macaqu
model
addit
rnadepend
rna
polymeras
rdrp
model
target
ribavirin
sequenc
analysi
model
dock
build
model
featur
increas
potenti
antivir
antivir
agent
remdesivir
design
ebola
viru
diseas
remdesivir
show
broadspectrum
antivir
activ
sever
rna
virus
may
compet
rdrp
remdesivir
ifnb
superior
antivir
activ
lpv
ritonavir
vitro
mous
model
sarscov
pathogenesi
prophylact
therapeut
remdesivir
improv
pulmonari
function
reduc
lung
viral
load
sever
lung
patholog
rhesu
macaqu
model
merscov
infect
prophylact
remdesivir
treatment
initi
h
prior
inocul
merscov
induc
clinic
diseas
replic
respiratori
tissu
thu
prevent
format
lung
lesion
cellbas
assay
triphosph
form
remdesivir
incorpor
posit
rna
chain
termin
delay
explain
high
potenc
remdesivir
rna
remdesivir
use
treat
first
case
infect
unit
state
patient
clinic
condit
improv
one
day
remdesivir
treatment
phase
ii
clinic
trial
remdesivir
perform
univers
nebraska
medic
center
phase
iii
clinic
trial
perform
chinajapan
friendship
hospit
result
clinic
trial
reveal
april
remdesivir
improv
pulmonari
function
reduc
lung
viral
load
amelior
sever
lung
patholog
contrast
prophylact
lpvrtvifnb
slightli
reduc
viral
load
impact
diseas
paramet
therapeut
lpvrtvifnb
improv
pulmonari
function
reduc
viru
replic
sever
lung
patholog
overal
result
indic
remdesivir
show
potenti
lpvrtvifnb
case
report
lopinavirritonavir
arbidol
associ
signific
improv
patient
efficaci
safeti
antivir
agent
assess
clinic
trial
thirtyfour
trial
antivir
agent
patient
regist
march
tabl
chloroquin
widelyus
antimalari
autoimmun
diseas
drug
report
potenti
broadspectrum
antivir
drug
chloroquin
known
block
viru
infect
increas
endosom
ph
requir
viruscel
fusion
well
interf
glycosyl
cellular
receptor
sarscov
first
result
obtain
patient
show
appar
efficaci
chloroquin
term
reduct
exacerb
pneumonia
durat
symptom
delay
viral
clearanc
absenc
sever
side
effect
chloroquin
includ
recommend
prevent
treatment
pneumonia
optim
dosag
chloroquin
need
assess
futur
trial
hydroxychloroquin
chloroquin
analog
fewer
concern
drugdrug
interact
previou
sar
outbreak
hydroxychloroquin
report
antisarscov
activ
vitro
use
physiologicallybas
pharmacokinet
pbpk
model
hydroxychloroquin
found
potent
chloroquin
vero
cell
cytokin
report
increas
respons
infect
may
progress
cytokin
storm
follow
multiorgan
failur
death
chloroquin
hydroxychloroquin
immunomodulatori
effect
suppress
immun
respons
therefor
clinic
studi
launch
chines
hospit
univers
oxford
evalu
efficaci
agent
infect
tabl
also
necessari
determin
whether
benefit
chloroquin
therapi
depend
age
patient
clinic
present
stage
diseas
clinic
data
confirm
biolog
result
chloroquin
hydroxychloroquin
may
use
prophylaxi
well
cur
treatment
individu
expos
studi
patient
receiv
corticosteroid
could
suppress
lung
inflamm
administ
dose
methylprednisolon
vari
depend
diseas
sever
current
interim
guidanc
clinic
manag
sever
acut
respiratori
infect
infect
suspect
releas
januari
advis
use
corticosteroid
unless
indic
anoth
reason
clinic
outcom
coronaviru
similar
outbreak
support
use
corticosteroid
retrospect
observ
studi
adult
critic
ill
mer
patient
given
corticosteroid
like
requir
mechan
ventil
vasopressor
renal
replac
therapi
manag
sar
corticosteroid
treatment
associ
psychosi
diabet
avascular
necrosi
overal
uniqu
reason
expect
patient
infect
benefit
corticosteroid
treatment
may
harm
howev
accord
clinic
experi
corticosteroid
could
prescrib
right
time
right
patient
clinic
trial
involv
corticosteroid
shown
tabl
develop
vaccin
therapeut
antibodi
import
implic
consid
rel
high
ident
receptorbind
domain
rbd
sarscov
crossreact
antisarscov
antibodi
spike
protein
assess
spike
protein
major
induc
neutral
antibodi
fortun
sarscovspecif
human
monoclon
antibodi
bind
potent
rbd
howev
sarscov
rbddirect
antibodi
bind
rbd
may
potenti
therapeut
candid
alon
combin
neutral
antibodi
prevent
treatment
infect
antibodi
design
treatment
ebola
viru
infect
significantli
reduc
mortal
ebola
viru
diseas
monoclon
antibodi
recogn
singl
antigen
epitop
limit
use
treatment
howev
develop
antibodi
requir
long
time
easi
appli
monoclon
antibodi
new
pathogen
clinic
practic
short
time
convalesc
plasma
administ
earli
symptom
onset
treatment
sar
pool
odd
mortal
follow
treatment
reduc
compar
placebo
therapi
odd
ratio
howev
ebola
viru
diseas
transfus
ml
convalesc
plasma
patient
associ
signific
improv
surviv
laboratori
test
viru
isol
bronchoalveolar
lavag
fluid
critic
ill
patient
could
neutral
sera
sever
patient
current
clinic
trial
involv
convalesc
plasma
transfus
shown
tabl
nation
health
commiss
china
appeal
convalesc
patient
donat
blood
treatment
infect
convalesc
plasma
collect
within
two
week
recoveri
ensur
high
neutral
antibodi
titer
difficulti
obtain
plasma
convalesc
limit
clinic
applic
welldesign
clinic
trial
need
evalu
efficaci
safeti
convalesc
plasma
therapi
patient
infect
structur
protein
reveal
enabl
rapid
develop
evalu
medic
countermeasur
address
ongo
public
health
crisi
find
provid
basi
studi
optim
vaccin
strategi
emerg
infect
major
vaccin
develop
coronavirus
target
spike
glycoprotein
protein
vaccin
develop
long
process
vaccin
avail
time
pandem
outbreak
exampl
ebola
epidem
outbreak
occur
three
year
later
rvsv
ebola
vaccin
select
phase
clinic
trial
safeti
immunogen
africa
europ
novemb
european
commiss
grant
market
author
merck
sharp
dohm
bv
europ
ebola
vaccin
ervebo
fortun
moderna
compani
announc
februari
compani
experiment
mrna
vaccin
known
readi
human
test
remark
fast
develop
cycl
develop
initi
vaccin
week
identifi
genet
sequenc
clinic
trial
safeti
immunogen
treatment
investig
clinicaltrialsgov
identifi
moreov
new
oral
vaccin
success
develop
tianjin
univers
use
foodgrad
safe
saccharomyc
cerevisia
carrier
target
protein
biotechnolog
compani
univers
china
work
vaccin
vaccin
develop
much
faster
ebola
collabor
effort
scientist
around
world
fasttrack
approv
vaccin
develop
effort
chines
health
organ
bat
recogn
natur
reservoir
vector
varieti
coronavirus
virus
cross
speci
barrier
infect
human
mani
differ
kind
anim
includ
avian
rodent
chiropt
origin
still
investig
featur
typic
coronavirida
famili
classifi
betacoronaviru
lineag
transmit
human
intervent
includ
intens
contact
trace
follow
quarantin
isol
effect
reduc
spread
effect
travel
restrict
wear
mask
wash
hand
disinfect
surfac
contribut
reduc
risk
infect
human
coronavirus
effici
inactiv
within
min
use
surfac
disinfect
procedur
ethanol
hydrogen
peroxid
sodium
hypochlorit
identif
caus
viral
pathogen
respiratori
tract
viral
infect
import
select
appropri
treatment
control
pandem
reduc
econom
impact
china
world
acut
respiratori
infect
rtpcr
routin
use
detect
caus
virus
respiratori
secret
posit
rate
pcr
oropharyng
swab
high
situat
swab
test
need
clarifi
diagnosi
typic
ct
find
help
earli
screen
suspect
case
diagnosi
infect
cluster
onset
like
affect
older
male
averag
age
year
comorbid
evid
support
advers
birth
outcom
intrauterin
infect
vertic
transmiss
howev
viral
infect
acquir
infant
pass
birth
canal
vagin
deliveri
postpartum
breastfeed
common
symptom
fever
cough
expector
headach
myalgia
fatigu
diarrhea
hemoptysi
peopl
may
experi
sever
acut
respiratori
distress
syndrom
histolog
examin
lung
biopsi
sampl
show
bilater
diffus
alveolar
damag
cellular
fibromyxoid
exud
organ
also
suscept
singlecel
rnaseq
data
use
analys
receptor
express
reveal
potenti
risk
differ
human
organ
infect
use
cell
entri
receptor
sarscov
regul
crossspeci
humantohuman
transmiss
proxim
tubular
cell
also
express
higher
level
receptor
lead
suscept
induc
kidney
injuri
data
patient
complet
clinic
cours
analys
level
blood
urea
creatinin
higher
nonsurvivor
survivor
patient
pneumonia
receiv
antibacteri
agent
receiv
antivir
therapi
receiv
methylprednisolon
clinic
trial
underway
investig
efficaci
new
antivir
drug
convalesc
plasma
transfus
vaccin
trial
initi
investig
studi
period
month
although
final
result
studi
take
long
time
complet
interim
research
data
may
provid
help
current
urgent
demand
therapi
pandem
public
health
emerg
intern
concern
countri
need
coordin
intern
effort
fight
transmiss
pneumonia
associ
yet
elimin
absenc
vaccin
antivir
isol
quarantin
achiev
remark
result
necessari
strengthen
monitor
develop
drug
vaccin
infect
soon
possibl
